Shared Experiences in Oncology & Rare Diseases: Recent Episodes
myTomorrows
Shared Experiences in Oncology & Rare Diseases is for everyone working in oncology and rare diseases, or simply interested in deepening their knowledge and enhancing professional and personal development. Topics like pre-approval access ethics, clinical trials, expanded access, maintaining a good work-life balance, practice tips and tricks as well as many more, are covered.
This episode features two guests who were trailblazers in the development of a landmark cancer drug. Gleevec (imatinib) was a breakthrough in cancer treatment because it helped establish a new group of drugs called targeted therapies. Join us to hear the experiences of Dr. James Shannon, former global head of pharma development at Novartis who helped bring Gleevec to market, and Mel Mann, an early participant in the Gleevec clinical trial who is now the world’s longest-living Gleevec patient.
Join us as we speak with Terri Ellsworth - rare disease key opinion leader and patient advocate. We learn about Terri's personal family experience with Duchenne muscular dystrophy, her work on behalf of patients and their parents as well as the advances that have been made in rare disease advocacy.
In this episode, we are in conversation with Tobias Polak - Director Real-World Data at myTomorrows. We discuss Tobias' views on how to optimize work efficiency, his role as Director Real-World Data, as well as his take on the industry’s state of play.
"Grip" by Rick Pastoor: https://rickpastoor.com/
Polak et al. Expanded Access as a source of real-world data: An overview of FDA and EMA approvals, Br J Clin Pharmacol, 2020
More about myTomorrows: https://mytomorrows.com/en